Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of BNT113 plus pembrolizumab versus pembrolizumab alone in first-line HPV16-positive PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
MOH_2024-05-30_013449Phase 2Not yet recruiting
- Sponsor
- BioNTech SE
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing BNT113 plus pembrolizumab with Pembrolizumab monotherapy (2 arms). Planned start Jan 2024; status: not yet recruiting.
02
Drugs
BNT113pembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2024-05-30_013449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-05-30_013449.